The Strange Case of ASML: Record Stock Price, Rock-Bottom Relative Valuation

As of April 2026, ASML traded at roughly 37 times forward earnings—only a 17% premium to Applied Materials. That is the narrowest premium since 2014, and it marks a dramatic shift from the much larger gap the company historically commanded thanks to its structural monopoly on extreme ultraviolet (EUV) lithography systems . In fact, ASML has even slipped to a discount against Lam Research, a dynamic unseen in 14 years, and now sits marginally below KLA on a forward P/E basis .

The structural overhangs: China, customer concentration, and earnings momentum

Several specific headwinds are compressing ASML's relative multiple, even as its absolute share price climbs.

One is China exposure. Ongoing export restrictions create persistent uncertainty over a revenue stream that has been material for ASML. Analysts note that China's own drive for domestic AI chip development will eventually require more advanced tools, but near-term sanctions risk remains a drag on sentiment .

Another is customer concentration and cyclical risk. Key logic and memory customers such as Intel and Samsung are navigating their own capital spending cycles and turnarounds, which tempers the pace of near-term orders compared with the broader U.S. equipment sector riding the hyperscaler capex wave .

Finally, there is straightforward earnings growth trajectory. The U.S. peers are directly levered to a surge in AI-related fab investment that has lifted their near-term earnings outlook more aggressively than ASML's, compressing the relative valuation gap even as ASML's own order book grows .

What analysts expect: broad optimism, wide disagreement

The consensus among Wall Street analysts is decidedly positive, but the range of opinion is unusually wide.

As of mid-2026, S&P Global data tracking 44 analysts shows a consensus rating of Strong Buy, with an average price target around $1,669 and a median near $1,737 . The highest target sits at $2,007, implying roughly 24% upside from current levels, while the most bearish estimate comes in at only $902, reflecting a possible drawdown of more than 40% .

After first-quarter earnings, a wave of major banks raised their targets. UBS, Citi, Deutsche Bank, and RBC Capital all lifted their estimates to between €1,600 and €1,700 on the Amsterdam-listed shares, roughly translating into U.S.-listed levels of $1,870 to $1,990 . Those upgrades largely reflect a raised full-year 2026 outlook from ASML, with net sales guided to between €34 billion and €39 billion and a growing backlog of High-NA EUV orders .

The bull case and the bear case

The analysts who see substantial upside argue that the compressed valuation itself is the signal. Historically, ASML's premium has expanded when order momentum accelerates, and with the semiconductor industry now entering the 2nm and 3nm node transitions, EUV demand is poised to rise. If China export fears ease or High-NA EUV shipments ramp faster than expected, the multiple could re-rate significantly . Bank of America has one of the highest targets among analysts, predicting production could reach 90 EUV tools annually by the end of 2027 .

On the other side, skeptics warn that much of the growth narrative is already priced in. The stock's valuation compression occurred despite strong earnings and a raised outlook, and any deceleration in EUV orders from TSMC or Intel could make current levels look stretched. The $902 low-end target from one analyst reflects genuine concern about the pace of High-NA adoption and the geopolitical overhang around China sales .

A historically unusual moment

ASML is not cheap in absolute terms, but it is remarkably cheap when measured against its own history and against the U.S. names that are its closest competitors. The 17% premium over Applied Materials and the discount to Lam Research are not normal—they are anomalies driven by a historic surge in American AI infrastructure spending that has left the Dutch monopoly stock looking almost like a value play by some measures.

Most analysts see moderate upside from current prices, with the average target implying roughly a 3.5% gain on the U.S.-listed ADR and the more bullish European targets suggesting significantly more room to run . The ultimate answer will depend on whether the AI capex rotation that has benefited American equipment makers so dramatically finally begins to lift all boats—or whether ASML's specific challenges keep the discount in place.